ALS drug gets backing by FDA panel after rare 2nd review
Patients with the deadly neurological disease have rallied behind the drug from Amylyx Pharma and are lobbying the FDA for approval.
Stay updated with breaking news from Billy Dunn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patients with the deadly neurological disease have rallied behind the drug from Amylyx Pharma and are lobbying the FDA for approval.
The Food and Drug Administration advisers voted 7-2 that data from Amylyx Pharma warranted approval, despite ongoing concerns about the strength and reliability of the company’s study. The vote is not binding a
An FDA advisory panel reversed its March decision to reject a novel drug for ALS, citing persuasive new evidence and clinician support.
A closely watched experimental drug for Lou Gehrig’s disease got an unusual second look from U.S. regulators on Wednesday, following intense pressure to...
A closely watched experimental drug for Lou Gehrig’s disease got an unusual second look from U.S. regulators on Wednesday.